Articles tagged with Cancer Medication
Researchers at Scripps Research and Mayo Clinic have identified a new class of senolytic drugs that can slow the aging process. These compounds, dasatinib and quercetin, selectively induce death in senescent cells, leading to improved cardiovascular function, exercise endurance, and extended healthspan.
A phase 2 clinical trial found that sunitinib significantly improved progression-free survival in patients with advanced differentiated thyroid cancer. The study showed that 83% of patients benefited from treatment, with either tumor shrinkage or slowed disease progression.
Researchers from Boston University School of Medicine shed new light on tumor metastasis, proposing a hypothesis that reversible epigenetic events regulate different types of metastatic cancers. Epigenetics enables cancer progenitor cells to differentiate into metastatic tumors.
A new study from Dana-Farber Cancer Institute found that many websites marketing personalized cancer care services make exaggerated claims, with 88% offering nonstandard tests lacking clear clinical utility. The researchers urge consumers and healthcare providers to critically evaluate these services.
Researchers at UC Davis have discovered a molecule that interferes with the internal regulation of cancer cells, causing them to self-destruct. This mechanism was found to be effective against glioma cells, which are responsible for a usually fatal type of brain cancer, and could be applicable to other highly aggressive cancers.
Researchers investigated a potential link between new weight-loss drugs and increased colon cancer risk, driven by the intestinal growth factor properties of glucagon-like peptide-1 (GLP-1). The study suggests that patients with a previous history or increased risk of colon cancer may not be ideally suited for these therapies.
Intermediate filaments of vimentin 'insulate' mitochondria in cancer cells from destruction, preserving energy reserves. This discovery may lead to the development of new drugs that effectively treat cancer.
Researchers found that a secreted immune protein called interleukin(IL)-17B promotes pancreatic cancer growth and metastasis. Treating tumor-bearing mice with an IL-17B inhibitor halted tumor growth and spread, resulting in increased survival.
A recent study by Samir Soneji found that the US spends significantly more on cancer treatment than Western European countries, yet mortality rates have decreased only modestly since 1970. The study suggests that much of this spending may be unnecessary and not leading to significant quality-adjusted-life-year gains.
A new nanodevice developed by MIT researchers can block the gene that confers drug resistance and then deliver a chemotherapy attack against disarmed tumors. The device was tested in mice implanted with human breast tumors and successfully shrunk tumors by 90% in two weeks.
Chemists at Bielefeld University develop copper-based anti-tumor agent that targets DNA phosphates, disrupting cellular processes and killing cancer cells. The new agent shows higher efficacy than cisplatin in killing cancer cells at lower concentrations.
A new study suggests that taking popular anti-smoking medication for several weeks before quitting may make it easier to quit and stay quit. The research found that extending the use of bupropion prior to quitting reduced smoking during that period without increasing craving or withdrawal.
A study published in JAMA Oncology found that 10% of CLL patients discontinued ibrutinib therapy due to disease progression. Patients who experienced Richter's transformation or progressive CLL had poorer outcomes and required alternative therapy quickly after discontinuation.
A new laboratory test, called Dynamic BH3 Profiling, can predict which cancer treatment will be most effective against a particular type of cancer within less than 24 hours. The test measures how vigorously tumor cells respond to different cancer drugs and has been shown to consistently predict the best treatment in clinical trials.
Researchers at Rockefeller University found that exposure to TGF-beta prompts changes in mouse tumor stem cells, making them more vulnerable to drugs. The study suggests that this environmental factor contributes to the unpredictable behavior of cancer cells and may lead to better treatment strategies for life-threatening cancers.
A new cancer drug called PAC-1, which targets cancer cells by restoring an enzyme's activity, is now entering phase I clinical trials in humans. The drug was first tested in pet dogs with spontaneously occurring cancers and showed promising results.
Cancer data in sub-Saharan Africa is being questioned due to its poor population coverage and weak registration systems. GLOBOCAN statistics are heavily relied upon by Governments and NGOs, despite lacking independent evaluation. Experts call for improved cancer registration systems and more transparency from the WHO.
Researchers from Dartmouth's Norris Cotton Cancer Center have discovered the Cherenkov Effect can be measured to improve radiation therapy. The study found that light emission correlates with dose, making it suitable for narrow beam stereotactic radiation therapy and surface dosimetry applications.
A new platform developed by UCLA bioengineers uses nanotechnology-enhanced medications and AI-driven analysis to create safer and more effective treatments for drug-resistant tumors. The approach, called Feedback System Control.II, has been shown to outperform traditional combination therapies.
A study found that a gene variant is associated with a higher incidence and severity of peripheral neuropathy in children treated with vincristine, a widely used anticancer agent. The variant, CEP72, was linked to an increased risk of nerve damage and pain in patients receiving vincristine treatment.
Researchers have identified potential targets for precision drugs that exploit cancer cells' inherent weaknesses in DNA repair systems. This discovery could lead to personalized medicine and potentially save thousands of cancer patients from chemotherapy's horrible side effects.
A common antibiotic, clarithromycin, has shown potential as an anti-cancer agent when used in combination with other drugs. Low- and middle-income countries may play a key role in developing this treatment, which could lead to improved patient outcomes.
Researchers at MD Anderson Cancer Center have identified unique 'protein patterns' in melanoma patients to predict resistance to BRAF inhibitors. These patterns may help guide personalized treatment decisions, including targeted agents or immunotherapies.
The phase II study results indicate that palbociclib can extend disease control and produce tumor shrinkage in ER+ breast cancer patients. Researchers observed significantly longer progression-free survival in hormone receptor-positive patients compared to those with HR-negative breast cancer.
Abl and Src proteins have distinct evolutionary paths, allowing Brandeis researchers to pinpoint specificity for Gleevec. Their findings pave the way for rational drug design in various cancers.
Researchers at UT Southwestern Medical Center found that acetate supplements accelerate tumor growth and metastasis in mice. The study suggests that modulating acetate production could be a key to designing therapies for cancer patients.
Researchers found a genomic marker that could help identify patients most likely to benefit from cabazitaxel, a newer member of the taxane family. The study suggests that cabazitaxel may be more effective sooner in treatment for some patients with prostate cancer.
Researchers discovered a key pathway driving tumour growth in bile duct cancer and found that blocking it can prevent cancer cell growth and shrink tumours. The treatment is already being tested in patients with other cancers and shows promise as a potential breakthrough for this devastating disease.
Researchers at Mayo Clinic have identified Stearoyl-CoA desaturase 1 as an oncogenic enzyme crucial to the survival of anaplastic thyroid carcinoma cells. Inhibiting this molecule has been shown to effectively shut down ATC cell growth and induce cell death.
A team of NUS researchers developed a novel strategy to prevent inflammation-associated cancers by targeting the interaction between FAT10 and MAD2. This approach facilitates the development of cancer drugs with fewer side effects, as it targets specific pathological functions without affecting other physiological functions.
Dartmouth investigators develop new algorithms that employ molecular modeling to optimize deimmunized drug candidates. The approach resulted in highly-active and stable biotherapeutic designs that addressed immunogenic hotspots not easily targeted by earlier methods.
Researchers have developed a new algorithm called Gene Rank (GR) to describe gene connectivity, which can be used for disease prognosis and early cancer detection. GR is based on gene expression data and reflects how well a particular gene is connected to other genes.
A study published in JAMA Oncology found that at least one clinically relevant genomic alteration was present in most samples tested, suggesting a potential for personalized therapy. The research analyzed 200 cancer of unknown primary site (CUP) samples and identified 169 specimens with potentially targetable genomic alterations.
A new approach, called an evolutionary trap, steers cells into one evolutionary path while shutting off others, then knocks out the cell population for good. The strategy may be applied to various clinical scenarios where drug resistance is a problem.
Researchers at the University of Manchester developed heat-activated liposomes with antibody targeting capabilities, showing improved drug delivery to tumour tissue in mice. The combination approach resulted in a moderate improvement in animal survival, offering potential for novel targeted drug delivery strategies.
Researchers at Harvard Medical School and University of Waterloo have discovered a new lethal combination of cancer drugs that can shrink tumors and extend the survival of mice with cancer. The study found that targeting specific protein Hck can kill transitioning cells between non-Cancer Stem Cells (CSCs) and CSCs.
The OHSU Knight Cancer Institute awarded $462,656 to 17 projects statewide to address community-identified needs and decrease the impact of cancer on Oregonians. The funded projects focus on preventing tobacco use among youth, increasing colorectal cancer screening, and developing skin cancer prevention programs.
Franziska Michor's research combines evolutionary biology, mathematics, and clinical research to better understand cancer genesis and treatments. Her work has furnished a precise understanding of drug resistance and led to the development of novel cancer treatment regimens.
Researchers at the University of Cincinnati found that SapC-DOPS can selectively target and kill lung cancer cells while sparing normal cells. The nanovesicle delivery system has shown promising results in animal models and human cell cultures, offering hope for a targeted treatment option for this deadly disease.
A study published in Nature identified axitinib as a promising drug candidate for treating drug-resistant leukemia. The researchers used a novel screening method and partnered with Pfizer to define the mechanism of action, providing new insights into blocking cancer-causing kinases.
A recent UCSF-led study identified YAP as a key driver of resistance to targeted cancer therapies. By suppressing YAP, the researchers found that combination therapies targeting both MEK and YAP pathways can enhance the effectiveness of individual drugs in treating BRAF- and RAS-mutant tumors.
G1 Therapeutics, a UNC-Chapel Hill spinout, has secured $33 million in Series B funding to accelerate clinical development of its lead CDK4/6 inhibitor for cancer treatment. The company aims to develop more effective and less toxic methods to treat patients with cancer.
Two-thirds of primary care health professionals want to widen exemption criteria for long-term conditions and lower or abolish charges altogether. The current system is seen as a barrier that prevents some people from receiving necessary prescriptions.
Researchers have developed a new technique called iontophoresis that delivers high concentrations of chemotherapy directly to tumors, reducing the risk of damaging healthy tissue. This technology has the potential to improve treatment outcomes for cancer patients by allowing for more potent anti-cancer drugs to be used.
Researchers at Dartmouth have found that introducing a specific strain of bacteria into the microenvironment of ovarian cancer tumors can transform tumor cells from suppressors to attackers, sparking a strong anti-tumor immune response. The study's results demonstrate a new potential for treating various types of cancers.
A new research by Dr Alessandra Ghigo found that inhibiting the activity of phosphoinositide 3-kinase gamma (PI3K?) protected mice with hypertension from developing heart failure. The study also showed that a PI3K? inhibitor could synergise with chemotherapy to delay tumour growth and prevent cardiotoxicity.
A University of Colorado study finds alterations in expression of PIK3R3 and PTEN genes in young-adult Ewing Sarcoma, commonly observed in adult tumors. These findings could lead to adapted therapeutic strategies for adult cancers to treat Ewing Sarcoma.
Researchers analyzed data from Medicare and VA patients, revealing that physicians' prescribing decisions are influenced by multiple factors, including patient costs and regional variations. The study highlights the need for improvement in healthcare systems to optimize treatment selection and reduce costs.
Researchers at Dartmouth's Norris Cotton Cancer Center have identified ERBB4 as a driver protein in breast cancers that have developed resistance to HER2 targeted therapies. The discovery suggests that anti-ERBB4 drugs could be highly beneficial for patients who no longer respond to first or second-line treatments.
The Damon Runyon Cancer Research Foundation has awarded over $3.76 million in fellowships and Breakthrough Scientist awards to 15 new recipients, providing them with independent funding to pursue innovative projects. The fellows will focus on novel ideas and approaches to combat cancer.
Scientists have made the largest ever catalogue of biological chimeras available to the public domain. The new database comprises over 29,000 small RNA molecules that originate from different genomic regions, which could reveal useful markers for clinical oncology practice and novel drug targets for cancer treatment.
A comprehensive catalog of genetic mutations has been published for 279 head and neck cancers, revealing distinct genetic profiles for HPV-positive and -negative patients. This finding may lead to the development of targeted therapies and improved outcomes for these cancer types.
A study from Boston Children's Hospital and Dana-Farber Cancer Institute found that an existing epigenetic drug can increase the effectiveness of chemotherapy for patients with non-small-cell lung cancer (NSCLC) who have BRG1 or EGFR mutations. This breakthrough suggests a new approach to precision medicine in cancer treatment.
A new study published in Diabetologia found that cancer patients with diabetes have significantly lower medication adherence rates compared to those without diabetes. The research revealed that the type and stage of cancer had a significant impact on medication adherence, with more advanced cancers resulting in substantially lower rates.
Researchers have discovered a way to eradicate cancer stem cells using antibiotics, opening up the possibility of a new treatment for cancer. The study found that four types of antibiotics eradicated cancer stem cells in every test, including glioblastoma and other aggressive forms of cancer.
Researchers at UMD have developed a technology platform for creating targeted drug and vaccine delivery vehicles using customized soap bubbles. The technology can produce 1,000 doses of vaccines in just 72 hours.
The study found genomic similarities between head and neck cancer genomes and other cancers, including squamous cell lung and cervical cancer. Researchers also identified potential new drug targets and biomarkers for treating HPV-related head and neck cancers.
The GW Cancer Institute will launch a yearlong study to gather key information about barriers encountered by patients with cancer, create evaluation tools for patient navigation at the community level, and translate research findings for practice-based audiences.
Scientists at the University of York found that phenytoin reduces tumour growth and cell proliferation in breast cancer models. The study suggests repurposing antiepileptic drugs as a novel therapy for cancer, worthy of further investigation.
A survey of 364 medical journalists found that direct contact with physicians is the most reliable source of information for creating accurate cancer news. Medical journalists also rely on social media and personal connections to support their research, highlighting the need for responsible healthcare reporting.